Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM.

Enferm Infecc Microbiol Clin. 2017 May 19. pii: S0213-005X(17)30133-7. doi: 10.1016/j.eimc.2017.04.002. [Epub ahead of print] English, Spanish.

PMID:
28532596
2.

Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la Torre J, Tuset M, Gatell JM.

Enferm Infecc Microbiol Clin. 2017 Feb;35(2):88-99. doi: 10.1016/j.eimc.2016.06.013. Epub 2016 Jul 25.

PMID:
27459919
3.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Review.

PMID:
27056581
4.

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.

Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5.

5.

Co-occurrence of myasthenia gravis with Parkinson's disease: A not to be missed diagnosis.

Tung-Chen Y, Bataller L, Sevilla T, López-Aldeguer J.

Geriatr Gerontol Int. 2016 Apr;16(4):528-30. doi: 10.1111/ggi.12558. No abstract available.

PMID:
27037723
6.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

PMID:
26976381
7.

Travelers' Diarrhea in Children at Risk: An Observational Study From a Spanish Database.

Soriano-Arandes A, García-Carrasco E, Serre-Delcor N, Treviño-Maruri B, Sulleiro E, Ruiz-Giardín JM, Sanmartín JV, Torrús D, Rojo-Marcos G, Cuadros J, Martín-Echevarría E, López-Vélez R, Molina I, Pérez-Molina JA; Redivi Study Group.

Pediatr Infect Dis J. 2016 Apr;35(4):392-5. doi: 10.1097/INF.0000000000001049.

PMID:
26974746
8.

Rate and predictors of progression in elite and viremic HIV-1 controllers.

Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C, Rallon N, Alcami J, Lopez-Aldeguer J, Viciana P, Rodriguez C, Grau E, Iribarren J, Gatell JM, Garcia F; EC and Immune Pathogenesis Working group of the Spanish AIDS Research Network.

AIDS. 2016 May 15;30(8):1209-20. doi: 10.1097/QAD.0000000000001050.

PMID:
26854807
9.

The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain.

Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V; Spanish HIV-2/HTLV Study Group.

AIDS Rev. 2015 Oct-Dec;17(4):212-9. Review.

PMID:
26616845
10.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group.

Lancet HIV. 2015 Nov;2(11):e464-73. doi: 10.1016/S2352-3018(15)00181-2. Epub 2015 Sep 30.

PMID:
26520926
11.

Extremely High Mutation Rate of HIV-1 In Vivo.

Cuevas JM, Geller R, Garijo R, López-Aldeguer J, Sanjuán R.

PLoS Biol. 2015 Sep 16;13(9):e1002251. doi: 10.1371/journal.pbio.1002251. eCollection 2015.

12.

Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected patients in the Spanish AIDS Research Network Cohort.

Torrecilla García E, Yebra Sanz G, Llácer-Delicado T, Rubio García R, González-García J, García García F, López-Aldeguer J, Asensi Álvarez V, Holguín Fernández Á; Cohort of the Spanish AIDS Research Network (CoRIS).

Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):353-60. doi: 10.1016/j.eimc.2015.07.016. Epub 2015 Sep 11.

PMID:
26364856
13.

Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.

Aldámiz-Echevarría T, González-García J, Von Wichmann MA, Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, Berenguer J.

Ann Hepatol. 2015 Jul-Aug;14(4):464-9.

14.

Consensus document on the management of renal disease in HIV-infected patients.

AIDS Working Group (GESIDA) of the Spanish Society of InfectiousDiseases and Clinical Microbiology (SEIMC); Spanish Society of Nephrology (S.E.N.); Spanish Society of Clinical Chemistry and Molecular Pathology (SEQC), Górriz JL, Gutiérrez F, Trullas JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofan F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gracia S, Iribarren JA, Knobel H, López-Aldeguer J, Lozano F, Martínez-Castelao A, Martínez E, Mazuecos MA, Miralles C, Montañés R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaría JM, Sanz J, Sanz J, Miró JM.

Nefrologia. 2014;34 Suppl 2:1-81. doi: 10.3265/Nefrologia.pre2014.Jul.12674. English, Spanish.

15.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):950-8. doi: 10.1093/cid/ciu939. Epub 2014 Nov 24.

PMID:
25422386
16.

Executive summary of the consensus document on the management of renal disease in HIV-infected patients.

Górriz JL, Gutiérrez F, Trullas JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofan F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gracia S, Iribarren JA, Knobel H, Lopez-Aldeguer J, Lozano F, Martínez-Castelao A, Martinez E, Mazuecos MA, Miralles C, Montañes R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaria JM, Sanz J, Sanz J, Miró JM.

Nefrologia. 2014 Nov 17;34(6):768-88. doi: 10.3265/Nefrologia.pre2014.Sep.12745. English, Spanish.

17.

Overall and cause-specific mortality in HIV-positive subjects compared to the general population.

Alejos B, Hernando V, López-Aldeguer J, Segura F, Oteo JA, Rubio R, Sanvisens A, Sobrino P, Del Amo J, Coris C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19711. doi: 10.7448/IAS.17.4.19711. eCollection 2014.

18.

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study.

Minguez C, Ortega E, Flores J, Carmena J, Masiá M, Montero M, Reus S, Tornero C, Galindo MJ, Garcia-Deltoro M, Amador C, Cuadrado JM, Usó J, López-Aldeguer J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19634. doi: 10.7448/IAS.17.4.19634. eCollection 2014.

19.

[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].

Panel de Expertos del Grupo de Estudio de Sida (GESIDA); la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); la Sociedad Española de Nefrología (SEN); la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC), Gorriz JL, Gutiérrez F, Trullàs JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofán F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gràcia S, Iribarren JA, Knobel H, López-Aldeguer J, Lozano F, Martínez-Castelao A, Martínez E, Mazuecos MA, Miralles C, Montañés R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaría JM, Sanz J, Sanz J, Miró JM.

Enferm Infecc Microbiol Clin. 2014 Nov;32(9):583-97. doi: 10.1016/j.eimc.2014.09.002. Epub 2014 Oct 7. Spanish.

PMID:
25303781
20.

HIV-2 and HTLV-1 infections in Spain, a non-endemic region.

de Mendoza C, Caballero E, Aguilera A, Pirón M, Ortiz de Lejarazu R, Rodríguez C, Cabezas T, González R, Treviño A, Soriano V; Spanish HIV-2/HTLV Group.

AIDS Rev. 2014 Jul-Sep;16(3):152-9. Review.

PMID:
25180694

Supplemental Content

Loading ...
Support Center